SRF fusion genes in myoid soft tissue tumors
The Journal of Pathology · 2026-12 · 270 (4) · 416-426
DOI: 10.1002/path.70114 ↗At a glance
Übersichtsarbeit in The Journal of Pathology, published online on 2026-08-19. Written by Ariane Sablon and 3 co-authors. Institution: de Duve Institute, UCLouvain, Brussels, Belgium. Major MEDLINE topics: Serum Response Factor, Soft Tissue Neoplasms, Gene Fusion, Oncogene Proteins, Fusion. 68 references. Funded by: Fonds de la Recherche Scientifique-FNRS.
Abstract (original language)
Serum response factor (SRF) is a ubiquitously expressed transcription factor that regulates immediate early genes, cytoskeletal organization, and muscle differentiation. Although SRF plays critical roles in development and cell growth, genomic alterations of SRF have long appeared absent in human neoplasms. Recently, however, recurrent SRF gene rearrangements have been identified in a spectrum of soft tissue tumors with myogenic features, including rhabdomyosarcomas, perivascular tumors, inflammatory myofibroblastic tumors, myoepitheliomas and peripheral nerve sheath tumors. This review summarizes current knowledge on SRF fusion genes and their biological and clinical implications. SRF fusions retain the N‐terminal DNA‐binding domain while replacing the native transactivation domain with that of a partner protein, frequently a transcription factor or co‐activator. This structural configuration leads to constitutive activation of SRF and dysregulation of transcriptional programs related to myogenesis, cytoskeleton organization, and, in some cases, inflammatory signaling. SRF ‐rearranged tumors predominantly affect children, usually display low‐grade behavior, and are often cured by complete surgical resection, although rare recurrences and metastases have been reported. Within perivascular myoid neoplasms, SRF ‐rearranged tumors show consistent phenotypic and clinical features, supporting their recognition as a distinct tumor entity, whereas SRF fusions identified in rhabdomyosarcomas and rare isolated cases likely represent separate biological contexts. Understanding SRF fusion‐driven transcriptional dysregulation provides insights into tumorigenesis and may inform future diagnostic and therapeutic strategies in myoid soft tissue neoplasms. © 2026 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- de Duve Institute, UCLouvain, Brussels, Belgium.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID profiles: Cristina R Antonescu, Jean-Baptiste Demoulin
Funding
- Fonds de la Recherche Scientifique-FNRS
Cite
APA
Sablon, A., Pirson, C., Antonescu, C. R., & Demoulin, J. B. (2026). SRF fusion genes in myoid soft tissue tumors. The Journal of Pathology, 270(4), 416-426. https://doi.org/10.1002/path.70114
Vancouver
Sablon A, Pirson C, Antonescu CR, Demoulin JB. SRF fusion genes in myoid soft tissue tumors. The Journal of Pathology. 2026;270(4):416-426. doi:10.1002/path.70114
BibTeX
@article{Sablon2026,
author = {Sablon, Ariane and Pirson, Constance and Antonescu, Cristina R and Demoulin, Jean-Baptiste},
title = {SRF fusion genes in myoid soft tissue tumors},
journal = {The Journal of Pathology},
year = {2026},
volume = {270},
number = {4},
pages = {416--426},
doi = {10.1002/path.70114}
}
EUVIMED